Status In progress
Process CDF Review
ID number 3885

Provisional Schedule

Committee meeting 07 April 2022
Expected publication 27 June 2022

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors AstraZeneca (durvalumab)
Others Department of Health and Social Care
  NHS England
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
29 November 2021 Invitation to participate
24 November 2021 In progress. Appraisal in progress.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance